Impact of Glucose Control and Regimen on Limb Salvage in Patients Undergoing Vascular Intervention
Background: Studies have demonstrated correlation between levels of glycated hemoglobin (HbA 1c ) in diabetic patients and the incidence of both peripheral artery disease and lower extremity amputation. However, the impact of glucose control on outcomes in patients undergoing open or endovascular treatment of peripheral artery disease has not been examined. The purpose of this study was to assess the effect of HbA 1c and medication regimen on amputation-free survival (AFS) in patients undergoing treatment for limb salvage.
Methods: Limb salvage patients with a baseline HbA 1c level within 1 month of treatment were identified from a prospectively maintained vascular registry queried from 2010 to 2017. The hospital electronic medical record was cross-referenced to identify patients with HbA 1c measured within 3 months of the index procedure. Patient records were examined, and instances of amputation, type of treatment (endovascular vs open), demographics, comorbidities, and diabetic glycemic control modalities were analyzed. Diagnosis of diabetes was determined by a combination of HbA 1c level, physician diagnosis, and use of diabetic medications.
Results: Our query found 306 eligible limbs for analysis. AFS was associated with diabetes (82.6%; P ¼ .002), nonwhite race (56.5%; P ¼ .006), insulin-only diabetic control (52.2%; P < .001), postoperative creatinine concentration >1.3 mg/dL (38.0%; P < .001), and dialysis (26.1%; P < .001; Background: Autologous vein is the preferred conduit for lower extremity bypass in patients with peripheral arterial disease (PAD) because of its superior patency. However, autologous vein is often unavailable because it has been previously harvested or is of inadequate caliber for a successful bypass. Cryopreserved veins and arteries are being increasingly used in these situations, although the literature reports patency rates inferior to those of both autologous vein and synthetic materials. Consequently, some authors have proposed that cryopreserved conduits should be used only as a last resort or only for critical limb ischemia. Extensive literature demonstrates that numerous cadaveric donor characteristics affect clinical outcomes in organ allotransplantation, but little is known about how donor characteristics affect vascular allotransplantation. Currently, variables having an impact on the patency of cryopreserved conduits remain an understudied area of clinical importance. The purpose of this study was to examine the risk-adjusted impact of cadaveric donor, patient, and operative characteristics on primary patency in patients undergoing lower extremity bypass. We hypothesized that increased warm ischemia times (WITs) would have a negative impact on the primary patency of these bypass grafts.
Methods: Clinical data for all patients who received a cryopreserved femoral artery, vein, or saphenous vein for lower extremity bypass for symptomatic PAD at a single-center institution from 2010 to 2016 were included for analysis. Patients' data were obtained from the institutional Clinical Data Repository and chart review. Allograft donor blood type and WIT were provided by the tissue processing organization. This study was approved by the Institutional Review Board with a waiver of consent because of its retrospective nature. This study's primary outcomes were primary patency and patient survival. Primary patency was defined according to the recommended reporting standards as detailed by Rutherford et al. In short, the graft is considered to have lost primary patency with interruption of flow by any means. Loss of primary patency was determined by objective testing including duplex ultrasound, computed tomography, and angiography; physical examination was not used for this assessment. Preoperative variables of interest were comorbidities, donor blood type, WIT, type of bypass, and use of arterial or venous allograft. Below-the-knee bypasses were classified as those with any infrageniculate target, including femoral below-the-knee popliteal and distal bypasses. Distal bypasses were classified as those to the tibioperoneal trunk and anterior or posterior tibial artery. Continuous variables are presented as mean 6 standard deviation and categorical variables as count (percentage). Patients were stratified by primary patency status for univariate analysis, either t-test or c 2 test as appropriate. In addition, the impact of preoperative variables on time to loss of primary patency was evaluated using Kaplan-Meier analysis. A Cox proportional hazards model was used to determine risk-adjusted associations. All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
Results: A total of 60 patients with PAD underwent lower extremity bypass with 65 cryopreserved conduits during the study period. Primary patency at 1 year was 26.2%. Types of bypass were categorized into axillary-femoral (n ¼ 5), iliac-femoral (n ¼ 5), femoral-femoral (n ¼ 11), femoral-popliteal (n ¼ 11), popliteal-distal (n ¼ 4), and femoral-distal (n ¼ 29). Average survival was 581.5 6 559.7 days. The most common surgical indication was critical limb ischemia (64.6%; P < .01). Twenty-three WIT, Warm ischemia time. a The reference group used was the femoral-popliteal bypass group.
